Incyte (INCY) investor relations material

Strategic outlook and business evolution

• Transitioning from reliance on a single product to a diversified portfolio across hematology, oncology, and immunology, aiming for $3–$4 billion in core business revenue by 2030, up from $1.7 billion currently.

• Pipeline includes eight assets with potential to double company size, supported by 15 phase III clinical studies, with four high-probability assets expected to drive multi-billion dollar sales.

• Business development, exemplified by the Star Therapeutics acquisition, is focused on novel, high-impact assets in hematology to drive growth post-2029.

• The pipeline is expected to become the core business, targeting top quartile growth from 2029 through 2035.

Product launches and commercial execution

• Jakafi XR launched with strong early formulary coverage; sales expected to reach $50–$75 million by year-end, with a major conversion push anticipated in 2027.

• Uptake strategy focuses on prescriber and patient education, aiming to preserve over $1 billion in Jakafi sales if upper guidance is met.

• Sales and coverage updates will be provided regularly, with current sales at $10–$12 million.

Pipeline progress and regulatory strategy

• mCALR (INCB00989) shows high hematologic response rates and a clean safety profile in ET and MF, with pivotal trials in second-line ET and MF underway or planned.

• Regulatory discussions with FDA aim to establish a novel composite endpoint for MF trials, reflecting the drug’s impact on anemia and hematopoiesis.

• Three pivotal trials for mCALR expected to be ongoing by early 2027, targeting both ET and MF indications.